Anzeige
Meldung des Tages: Lithium ist zurück — und diesmal führen Institutionen den Markt an

Neurocrine Biosciences Aktie News

Aktie
WKN:  900964 ISIN:  US64125C1099 US-Symbol:  NBIX Branche:  Pharmazeutika Land:  USA
136,22 $
-1,15 $
-0,84%
115,16 € 23.01.26
Depot/Watchlist
Marktkapitalisierung *
12,30 Mrd. €
Streubesitz
-
KGV
20,38
neu: Nachhaltigkeits-Score
40 %
Index-Zuordnung
-

Neurocrine Biosciences News

21.01.26 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results PR Newswire
15.01.26 - PR Newswire
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
Neurocrine Biosciences Presents Head-​to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR PR Newswire
05.01.26 - PR Newswire
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
22.12.25 - PR Newswire
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy PR Newswire
16.12.25 - PR Newswire
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology PR Newswire
09.12.25 - PR Newswire
Neurocrine Biosciences to Host R&D Day on December 16
Neurocrine Biosciences to Host R&D Day on December 16 PR Newswire
20.11.25 - PR Newswire
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-​Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) ...
11.11.25 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences
Neurocrine Biosciences to Present at Upcoming Investor Conferences PR Newswire
10.11.25 - PR Newswire
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder PR Newswire
28.10.25 - PR Newswire
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results PR Newswire
17.10.25 - PR Newswire
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules PR ...
07.10.25 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results PR Newswire
06.10.25 - PR Newswire
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise PR Newswire
06.10.25 - PR Newswire
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Neurocrine Biosciences Presents New Three-​Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for ...
23.09.25 - PR Newswire
Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden
Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While ...
22.09.25 - PR Newswire
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder PR Newswire
16.09.25 - PR Newswire
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 PR Newswire
26.08.25 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September PR Newswire
06.08.25 - PR Newswire
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference PR Newswire
30.07.25 - PR Newswire
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results PR Newswire

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »